Lloyds Enterprises: Secures ₹219 Crore Loan for Steel Infra Acquisition

Lloyds Enterprises Limited has entered into a significant loan agreement with Tata Capital Limited for ₹219,00,00,000. This financial assistance is earmarked for the acquisition of equity shares in Steel Infra Solutions Company Limited and associated transaction expenses. The agreement underscores the company’s strategic expansion initiatives in the equity market.

Lloyds Enterprises Secures Major Funding for Acquisition

Lloyds Enterprises Limited has announced the execution of a loan agreement with Tata Capital Limited, securing ₹219,00,00,000 (Rupees Two Hundred and Nineteen Crores). This substantial financial facility is intended to fund the proposed acquisition of equity shares in Steel Infra Solutions Company Limited. The loan will also cover related transaction expenses, marking a significant step in the company’s growth strategy.

Acquisition Details and Loan Terms

The acquisition involves 73,00,000 equity shares of Steel Infra Solutions Company Limited, with an aggregate consideration amounting to approximately ₹219,00,00,000. The loan is structured as a secured facility, with the security provided being a pledge of equity shares of Lloyds Engineering Works Limited held by Lloyds Enterprises Limited. The loan agreement was executed on August 13, 2026. As of the execution date, the total amount outstanding on this loan facility is ₹219,00,00,000. The company also reported a cumulative total outstanding loan amount of ₹316,00,00,000 (Rupees Three Hundred and Sixteen Crores) across its various borrowing arrangements.

No Related Party Transactions

Lloyds Enterprises confirmed that the parties to the agreement are not related to the promoter/promoter group or group companies. Furthermore, the transaction is not considered a related party transaction and is conducted at arm’s length. There are no significant special terms in the agreement, nor is there any shareholding of the lender in the target entity.

Source: BSE

Previous Article

Aurobindo Pharma: Q1 FY27 Earnings Call Highlights Growth and Strategic Progress

Next Article

Kothari Fermentation: Q1 2026 Unaudited Results Show Profit After Tax